Your session is about to expire
← Back to Search
Glofitamab + Chemotherapy for Non-Hodgkin's Lymphoma
Study Summary
This trialevaluates a new combination treatment for people with DLBCL that have failed a prior line of therapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had a stem cell transplant from a donor.I am on a stable dose of corticosteroids not exceeding 30 mg/day for at least 4 weeks.I have or had a brain-related condition like stroke or epilepsy.I am eligible for intense chemotherapy followed by stem cell or CAR-T therapy.I had a stem cell transplant for a condition other than lymphoma within the last 5 years.I haven't had monoclonal antibody cancer treatment in the last 4 weeks.My side effects from previous cancer treatments are mild, except for hair loss or loss of appetite.I am currently being treated for an autoimmune disease.I have been diagnosed with progressive multifocal leukoencephalopathy.My cancer is a type of B-cell lymphoma confirmed by lab tests.My nerve damage is not severe.I have or might have had HLH.I have been treated with glofitamab or similar drugs.I have or had lymphoma in my brain or spinal cord.I have had more than one treatment for diffuse large B-cell lymphoma.I have been diagnosed with primary mediastinal B-cell lymphoma.I am fully active or can carry out light work.I have had a stem cell transplant for lymphoma.I have not had major surgery in the last 4 weeks.My cancer came back or didn't respond after my first chemoimmunotherapy.I have a significant history of liver disease.I have had a solid organ transplant.I haven't taken any immune-weakening medications in the last 4 weeks.I have had one treatment that included rituximab and an anthracycline.I haven't had cancer treatments like chemo or immunotherapy in the last 2 weeks.
- Group 1: R/R DLBCL
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the current cohort size of this research endeavor?
"The trial's sponsor, Hoffmann-La Roche, requires 40 patients that meet their inclusion criteria. These patients will be recruited from the New york University Langone Medical Center and UMASS Memorial Medical Center in Worcester."
What risks come with the progression of relapsed or refractory diffuse large B-cell lymphoma?
"The safety of R/R DLBCL has been assessed at a score of 1, as this is an early stage clinical trial with only restricted data that supports its efficacy and security."
Are participants being recruited to take part in this experiment?
"Clinicaltrials.gov indicates that this research study is actively recruiting participants; the trial was published on November 4th 2022 and revised for accuracy most recently on November 16th of the same year."
Share this study with friends
Copy Link
Messenger